Close Menu

More articles about Diagnostics

Promega will develop its microsatellite instability assay as a companion diagnostic for Incyte's anti-PD-1 drug candidate retifanlimab in endometrial cancer.

A consortium led by the Barcelona-based company recently received €150,000 in EU funding to bring the platform to market.

The nonexclusive deal includes Personal Genome Diagnostics' US Food and Drug Administration-cleared Elio Tissue Complete cancer genomic profiling assay.

Illumina thinks the next-generation sequencing cancer testing market will grow to $75 billion over the next 15 years, driven by screening.

Along with the downgrade, the investment bank also lowered its December 2021 price target for Illumina from $390 to $280.

The diagnostics are capable of detecting fewer than two parasites per microliter of blood and would cost an estimated $.61 per test.

As part of the award, Ortho Clinical will develop a rapid SARS-CoV-2 antigen assay and further develop its two FDA-authorized SARS-CoV-2 antibody assays.

The Wilmington, Delaware-based startup will use the funds for clinical validation trials on its Arna Breast cancer diagnostic test in the US and Europe. 

After a two-year evaluation in advanced non-small cell lung cancers with Allegheny Health Network, the payor will cover the test for its regional members.

The deal, which was approved by the boards of directors of both companies, is expected to close in the second half of 2021, pending customary conditions.

An early version of the test is being used by researchers as part of the NIH-funded Chronic Renal Insufficiency Cohort (CRIC) study.

The deal includes UK-based Yourgene's test for detecting cancer patients who may have an adverse reaction to 5-fluorouracil, as well as reproductive health tests.

An initial program aims at the development of a serum neurofilament light chain immunoassay to support Novartis' MS and other neuroscience programs.

One of the revisions specifies that the ID Now test is for use with specimens collected within the first week of symptom onset.

The agency confused and upset many in the healthcare community last month when it said asymptomatic patients did not need to be tested.

The test targets antibodies for the viral spike protein and can characterize a vaccine-induced immune response.

The tests will be developed to identify NSCLC patients with ALK fusions and EGFR Exon20 insertion mutations who respond to mobocertinib or brigatinib.

Visby's test is a fully integrated PCR device that detects SARS-CoV-2 RNA, while SNIBE's test comprises assays for two different antibodies against the virus.

The test, which received EUA from the US Food and Drug Administration in April, is designed to detect human IgG antibodies in serum and plasma.

The startup wants to serve the 50 percent or so of genetic disease patients who haven't obtained a molecular diagnosis despite extensive testing.

Pages